Overview

Study of Ipilimumab in the Immune System

Status:
Completed

Trial end date:
2017-10-01

Target enrollment:

Participant gender:

Summary

Participants will be taking 3 mg/kg ipilimumab intravenously over a 90-minute period every 3 weeks for a total of four doses. Tumor-infiltrating lymphocytes (TILs)will be analyzed for functional characteristics.

Phase:

N/A

Details

Lead Sponsor:

University Health Network, Toronto

Treatments:

Antibodies, Monoclonal
Ipilimumab